Physician profile
Robert Martin
NPI 1548385339
$1,531.28
in general payments reported to CMS, 2019-2025
13 companies · $16.63 in 2025
The $16.63 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $509 · 2023: $430 · 2024: $371 · 2025: $16.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.52 | 2022 | |
| Nevro Corp. | $114.88 | 2023-2024 | Senza |
| Lilly USA, LLC | $53.76 | 2021-2024 | Reyvow, Emgality |
| Pfizer INC. | $51.92 | 2023 | |
| Merz Pharmaceuticals, LLC | $51.11 | 2023 | Xeomin |
| Grt US Holding, INC. | $46.20 | 2021-2022 | |
| Allergan, INC. | $44.65 | 2021-2022 | |
| Nalu Medical, INC. | $33.81 | 2024 | Nalu Neurostimulation System |
| Biohaven Pharmaceutical Holding Company LTD. | $32.27 | 2022 | |
| Depuy Synthes Sales INC. | $27.33 | 2023-2024 | Monovisc, Orthovisc |
| Vertos Medical, INC. | $18.74 | 2023 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $14.37 | 2024 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.